Systemic Immune-Inflammation Index as a Prognostic Marker of Late Recurrence in Operable Gastric Cancer: a Dual-Center Study

Emre Yekedüz1,2,7 · İzzet Dogan3 · Dişła Mızrak Kaya4 · İlker Ö zgür5 · Üngör Utkan1,2 · Sezai Vat ans e ve r3 · Salim Demirci2,6 · Hakan Akbulut1,2 · Yüksel Ürün1,2

Accepted: 15 November 2021 / Published online: 30 November 2021
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021

Abstract

Aim To evaluate the prognostic role of the systemic immune-inflammation index (SII) in patients with operable gastric cancer.

Methods We assessed 354 patients with operable gastric cancer from tertiary centers in Turkey. SII was calculated by following formula: \[
\text{SII} = \frac{\text{neutrophil} \times \text{platelet}}{\text{lymphocyte}}
\] The best cut-off value for SII was determined by using “receiver operating characteristics (ROC)” analysis. We used log-rank and Cox-regression analysis for survival analyses.

Results One hundred twenty patients were in the late recurrence group (recurrences have developed 36 months after the surgery). SII was not a prognostic factor in the early recurrence group. However, relapse-free survival (RFS) was longer in SII-low patients than SII-high patients in the late recurrence group. In multivariable analysis, SII was the only independent prognostic factor for RFS in the late recurrence group (hazard ratio (HR): 5.42, 95% CI: 1.18–24.82, \(p = 0.03\)).

Conclusion SII was an independent prognostic factor for RFS in GC patients with late recurrence. Late recurrence risk was higher in SII-high patients than SII-low patients. Inflammation contributes to tumor progression, invasion, and metastasis. Prolonged exposure to chronic inflammation could explain the results of this study.

Keywords Gastric cancer · Prognosis · Systemic immune-inflammation index

Introduction

Localized gastric cancer (GC) still has a higher recurrence rate despite improvements in surgical techniques and adjunctive treatment options [1]. Most recurrences are observed within the first 2–3 years after surgery [2]. Approximately 90% of recurrences occur in the first 3 years.

Immunity is the mainstay of fighting against cancer. With the start of the immunotherapy era, tumor immunity became more popular in cancer research. However, immunity plays a dual role in cancer development. Hosts’ immune response against tumors is crucial in cancer treatment. On the other hand, uncontrolled tumor-associated systemic inflammation increases tumor growth, angiogenesis, metastasis, and resistance to cancer treatment [3–5].

Neutrophil and platelet counts are considered the main markers in response to inflammation. Both increase with the inflammation [6, 7]. Lymphocyte is the chef of orchestra in the immune response against the tumor. In this regard,
declining in lymphocyte count may cause a poor prognosis [8].

There are multiple options combining neutrophil, platelet, and lymphocyte as a prognostic factor in cancer patients. Neutrophil to lymphocyte ratio, neutrophil to platelet ratio, and systemic immune-inflammation index (SII) are the most known inflammatory markers used to predict survival in solid tumors [9–11].

Besides the unknown mechanisms for early and late recurrences of GC, the extent of the performed surgery, pathological T and N stages, histological type, and the adequacy of the adjunctive treatment were the well-known factors to predict early and late recurrences of GC [12]. Also, different clinicopathological factors may play a prognostic role in the early and late recurrence groups [13, 14]. In this study, we aimed to assess the prognostic value of SII for (relapse-free survival) RFS in the operable gastric cancer patients with early and late recurrence.

Methods

We conducted this retrospective study in two cancer research centers (i.e., Ankara University and Istanbul University) in Turkey. The local ethical committee approved this study.

Patient Cohort

Patients diagnosed with gastric cancer between 01.01.2004 and 31.12.2019 were determined using the “International Classification of Disease” codes. We included all operable gastric cancer patients older than 18 years in this study and excluded the patients with distant metastasis at diagnosis, gastric lymphomas, gastrointestinal stromal tumors, and other than a primary tumor of the stomach, and patients who underwent R2 resection. Of note, we included all patients who met the inclusion and exclusion criteria irrespective of lymphadenectomy type (D1 or D2). Because of the retrospective nature of this study, the type of lymphadenectomy was based on the surgeon preference.

Data Extraction and Analysis

Electronic patient records were searched. Patients’ clinical and pathological data were extracted to the database. Patients with recurrence within 36 months after surgery were grouped as early recurrence, and the remaining patients were grouped as late recurrence. To calculate SII, we used following formula: \[ \text{SII} = \frac{\text{neutrophil (cells} \times 10^9/L) \times \text{platelet (cells} \times 10^9/L)}{\text{lymphocyte (cells} \times 10^9/L)} \]. All values were obtained from a complete blood count (CBC) performed in the last month before surgery. If there were more than one CBC result, the closest to the surgery time was used. The best cut-off value for SII was determined using “receiver operating characteristics (ROC)” analysis; thus, an SII value equal to 708 × 10^9/L was the best cut-off point with 52.3% sensitivity and 52.1% specificity for RFS.

Statistical Analysis

Descriptive analyses were presented using mean ± standard deviation or median with interquartile range (IQR) for continuous variables and percentages for categorical variables. Independent samples t-test or Mann–Whitney U test for continuous variables and chi-square or Fisher’s exact test for categorical variables were performed to compare the variables. Univariable and multivariable survival analyses were performed with the log-rank test and Cox proportional hazards regression model. Kaplan–Meier survival estimates were also calculated. A p-value of less than 0.05 was considered to show a statistically significant result. ROC analysis was performed to determine the best cut-off value for SII. We used SPSS 27.0 for Mac (IBM Corp., Armonk, NY) for all statistical analyses.

Results

A total of 354 patients were included in this study. There were 234 (66.2%) and 120 (33.8%) patients in the early and late recurrence groups, respectively. The median follow-up was 25.5 months (IQR: 15.9–50.7). The median RFS was 57 months (95% confidence interval (CI): not calculated), and the median overall survival (OS) was 136.4 months (95% CI: 98.6–174.3) for all patients. Five-year OS and RFS rates were 64% and 48%, respectively. The median RFS was 17.9 months (95% CI: 16.1–19.7) for the early recurrence group. However, the median RFS was not reached for the late recurrence group. Baseline characteristics of all patients are shown in Table 1.

SII was calculated for 83 patients in the late recurrence group. Baseline characteristics were similar in the SII-low and SII-high patients (Table 2). In the early recurrence group, the median RFS was 19.1 months (95% CI: 16.2–21.9) and 17.9 months (95% CI: 15.6–20.3) for SII-low and SII-high patients, respectively. There was no statistical significance between the groups (log-rank p = 0.8) (Fig. 1a). In the late recurrence group, the median RFS was not reached for SII-low and SII-high patients. However, RFS was better in SII-low patients than SII-high patients (log-rank p = 0.028) (Fig. 1b). After adjusting for confounding factors (i.e., age, tumor grade, pathological N stage, adjuvant treatment), SII was the only factor associated with RFS in the late recurrence group. Late recurrence risk was higher in SII-high patients than SII-low patients (hazard ratio (HR): 5.42, 95% CI: 1.18–24.82, p = 0.03) (Table 3).
|                                | Early recurrence (≤ 36 months) | Late recurrence (> 36 months) |
|--------------------------------|-------------------------------|-------------------------------|
|                                | \( n = 234 \) (%)             | \( n = 120 \) (%)             |
| Age-years, median (IQR)        | 58 (50–65)                    | 53 (47–59)                    |
| Sex                            |                               |                               |
| Male                           | 158 (68)                      | 77 (64)                       |
| Female                         | 76 (32)                       | 43 (36)                       |
| Tumor location                 |                               |                               |
| Proximal                       | 59 (25)                       | 32 (27)                       |
| Mid                            | 37 (16)                       | 20 (17)                       |
| Distal                         | 93 (40)                       | 55 (46)                       |
| Grade                          |                               |                               |
| 1                              | 8 (3)                         | 15 (13)                       |
| 2                              | 67 (29)                       | 36 (30)                       |
| 3                              | 113 (48)                      | 46 (38)                       |
| LVI                            |                               |                               |
| Yes                            | 182 (78)                      | 70 (58)                       |
| No                             | 14 (6)                        | 12 (10)                       |
| Pathological T stage           |                               |                               |
| 1                              | 11 (5)                        | 8 (6)                         |
| 2                              | 15 (6)                        | 15 (13)                       |
| 3                              | 86 (37)                       | 67 (56)                       |
| 4                              | 120 (51)                      | 28 (23)                       |
| Pathological N stage           |                               |                               |
| 0                              | 35 (15)                       | 30 (25)                       |
| 1                              | 44 (19)                       | 31 (26)                       |
| 2                              | 47 (20)                       | 30 (25)                       |
| 3                              | 106 (45)                      | 28 (23)                       |
| Histological type              |                               |                               |
| Signet-ring                    | 81 (35)                       | 36 (30)                       |
| Mucinous                       | 12 (5)                        | 7 (6)                         |
| Not specified                  | 140 (60)                      | 77 (64)                       |
| Lymph node dissection          |                               |                               |
| D1                             | 50 (21)                       | 24 (20)                       |
| D2                             | 182 (77)                      | 96 (98)                       |
| Resection                      |                               |                               |
|                  | Early recurrence |          | Late recurrence |          |
|------------------|------------------|----------|----------------|----------|
|                  | (≤36 months)     | (%)      | (> 36 months)  | (%)      |
| n = 234          |                  |          | n = 120        |          |
| R0               | 212 (90)         |          | 118 (98)       |          |
| R1               | 22 (10)          |          | 2 (2)          |          |
| Gastrectomy type |                  |          |                |          |
| Subtotal         | 138 (59)         |          | 67 (56)        |          |
| Total            | 96 (41)          |          | 53 (44)        |          |
| Adjuvant treatment |               |          |                |          |
| Chemotherapy     | 80 (34)          |          | 19 (16)        |          |
| Chemoradiotherapy| 138 (59)         |          | 89 (74)        |          |
| Radiotherapy     | 1 (1)            |          | 1 (1)          |          |
| None             | 15 (6)           |          | 11 (9)         |          |
| SII              |                  |          |                |          |
| Low (≤708 × 10⁹ cells/L) | 105 (45) |          | 41 (34)        |          |
| High (>708 × 10⁹ cells/L) | 103 (44) |          | 42 (35)        |          |

IQR interquartile range, LVI lymphovascular invasion, SII systemic immune-inflammation index
|                          | SII low                  |                  | SII high                  |                  | \( p \) value |
|--------------------------|--------------------------|------------------|--------------------------|------------------|---------------|
|                          | \( \leq 708 \times 10^9 \) cells/L | \( > 708 \times 10^9 \) cells/L |                          |                  |               |
|                          | \( n = 41 \)             | \( n = 42 \)     |                          |                  |               |
| Age-years, median (IQR)  | 53 (46–62)               | 58 (51–64)       |                          |                  | 0.08          |
| Sex                      |                          |                  |                          |                  | 0.6           |
| Male                     | 28 (68)                  | 27 (64)          |                          |                  |               |
| Female                   | 13 (32)                  | 15 (36)          |                          |                  |               |
| Tumor location           |                          |                  |                          |                  | 0.3           |
| Proximal                 | 14 (36)                  | 14 (37)          |                          |                  |               |
| Mid                      | 3 (8)                    | 7 (18)           |                          |                  |               |
| Distal                   | 22 (56)                  | 17 (45)          |                          |                  |               |
| Grade                    |                          |                  |                          |                  | 0.2           |
| 1                        | 1 (3)                    | 5 (13)           |                          |                  |               |
| 2/3                      | 32 (97)                  | 32 (87)          |                          |                  |               |
| LVI                      |                          |                  |                          |                  | 1             |
| Yes                      | 23 (89)                  | 18 (90)          |                          |                  |               |
| No                       | 3 (11)                   | 2 (10)           |                          |                  |               |
| Pathological T stage     |                          |                  |                          |                  | 1             |
| 1/2                      | 7 (17)                   | 7 (17)           |                          |                  |               |
| 3/4                      | 34 (83)                  | 34 (83)          |                          |                  |               |
| Pathological N stage     |                          |                  |                          |                  | 0.5           |
| 0                        | 8 (200)                  | 12 (29)          |                          |                  |               |
| 1                        | 9 (23)                   | 11 (26)          |                          |                  |               |
| 2                        | 14 (35)                  | 9 (21)           |                          |                  |               |
| 3                        | 9 (22)                   | 10 (24)          |                          |                  |               |
| Histological type        |                          |                  |                          |                  | 0.7           |
| Not specified            | 28 (68)                  | 30 (71)          |                          |                  |               |
| Signet-ring/mucinous     | 13 (32)                  | 12 (29)          |                          |                  |               |
| Lymph node dissection    |                          |                  |                          |                  | 0.5           |
| D1                       | 6 (150)                  | 8 (19)           |                          |                  |               |
| D2                       | 35 (85)                  | 34 (81)          |                          |                  |               |
| Gastrectomy type         |                          |                  |                          |                  | 0.9           |
| Subtotal                 | 22 (540)                 | 22 (52)          |                          |                  |               |
| Total                    | 19 (46)                  | 20 (48)          |                          |                  |               |
| Adjuvant treatment       |                          |                  |                          |                  | 0.7           |
| Chemotherapy             | 8 (20)                   | 10 (24)          |                          |                  |               |
This study was the first that assessed the prognostic effect of SII in GC patients with late recurrence to the best of our knowledge. We showed that SII was the only prognostic factor for RFS in the GC patients with late recurrence. Recurrence rates were higher for SII-high patients than SII-low patients in the late recurrence group. However, there was no prognostic effect of SII for RFS in the GC patients with early recurrence.

In a study evaluating prognostic effect of SII on operable GC patients, Wang et al. showed that SII was an independent prognostic factor for disease-free survival (DFS) and OS [15]. This study did not stratify the patients as early and late recurrence. In addition, 13% of all patients had R2 resection, and about 1 out of 4 patients had not received adjuvant chemotherapy. [15] However, no patient was performed R2 resection, and the rate of patients without adjuvant treatment was 7.3% in our study. Another study that included operable GC patients also showed that SII was an independent prognostic factor for DFS and OS. This study also showed that SII-low patients had a better prognosis than SII-high patients in 1, 3, and 5 years after surgery. [16] However, similar to the study of Wang et al., patients who underwent R2 resection and metastatic patients were included in this study [16].

In our study, we determined that SII could be a prognostic factor for late recurrences in operable gastric cancer, but not for early recurrences. It should be kept in mind that extent of resection and adjunctive treatment could affect the recurrence in patients with operable GC [17, 18]. Unlike the studies mentioned above, we did not include patients with R2 resection. Besides, the rate of adjuvant chemotherapy was higher in our study.

Tumor-associated inflammation is divided into three categories as preceding inflammation, tumor-elicited inflammation, and therapy-induced inflammation [5]. The calculation of SII before surgery may exclude the effect of therapy-induced inflammation. The prognostic impact of SII on the late tumor recurrence can be explained by the chronic effect of the inflammatory process. It is well-known that systemic inflammation contributes to tumor growth, metastasis, and therapy resistance [5]. Besides, increased tumor invasion and inhibition of adaptive immunity are considered a result of tumor-associated inflammation [19]. Neutrophil increases inflammation in the tumor microenvironment (TME) by secretion chemokines, cytokines, and reactive oxygen species (ROS), thus causes tumor growth and therapy resistance.
a) The Kaplan-Meier estimates of relapse-free survival - according to SII category in the patients with recurrence in three years

b) The Kaplan-Meier estimates of relapse-free survival - according to SII category in the patients with recurrence after three years
Table 3  Univariate and multivariate analysis for relapse-free survival (SII=Systemic Immune-Inflammation Index)

|                      | Univariate (log-rank) | Multivariate | $p$-value |
|----------------------|-----------------------|--------------|-----------|
|                      | $p$-value             | HR           | 95% CI    |           |
| Age                  | N/A                   | 1.01         | 0.95–1.07 | 0.6       |
| Sex                  | 0.4                   | 2            |           |           |
|                      | Male                  |              |           |           |
|                      | Female                |              |           |           |
| Tumor location       | 0.3                   | *            |           |           |
|                      | Proximal              |              |           |           |
|                      | Mid                   |              |           |           |
|                      | Distal                |              |           |           |
| Grade                | 0.2                   | 1            |           | 0.3       |
|                      | 1                     | 1            |           |           |
|                      | 2                     | 6.7          | 0.35–127.84 |       |
|                      | 3                     | 2.3          | 0.19–28.71 |           |
| LVI                  | 0.7                   | *            |           |           |
|                      | No                    |              |           |           |
|                      | Yes                   |              |           |           |
| Pathological T stage | *†                   | *            |           |           |
|                      | 1/2                   |              |           |           |
|                      | 3/4                   |              |           |           |
| Pathological N stage | 0.06                  | 1            |           | 0.1       |
|                      | 0                     | 1            |           |           |
|                      | 1                     | 1.97         | 0.16–23.53 |       |
|                      | 2                     | 10.12        | 1.03–99.17 |           |
|                      | 3                     | 9.27         | 0.88–97.62 |           |
| Histological type    | 0.7                   | *            |           |           |
|                      | Not specified         |              |           |           |
|                      | Signet-ring/mucinous  |              |           |           |
| Lymph node dissection| 0.8                   | *            |           |           |
|                      | D1                    |              |           |           |
|                      | D2                    |              |           |           |
| Gastrectomy type     | 0.6                   | *            |           |           |
|                      | Subtotal              |              |           |           |
|                      | Total                 |              |           |           |
On the other hand, platelets also have a significant effect on tumor-associated inflammation. It plays an essential role in tumor angiogenesis. Furthermore, cytokines secreted by platelet contribute to tumor-associated inflammation in the TME; thus, causing drug resistance.

Our study suggested that more prolonged chronic inflammation may be associated with recurrence. To date, there was no clear evidence for the relation between the duration of inflammation and cancer recurrence in the operable solid tumors. However, it is well-known that the duration of chronic inflammation is one of the critical factors for cancer pathogenesis. The prognostic effect of SII on the late recurrences may be explained with prolonged exposure to chronic inflammation.

Recently, a study conducted by Hirahara et al. did not show the prognostic value of SII on OS in the overall population. Similar to our study, there were no patients with R2 resection in this study. However, Hirahara et al. showed that SII was a prognostic factor in elderly patients. In fact, it may be contributed to our hypothesis regarding the association between the late recurrence and more prolonged chronic inflammation exposure.

Our study has several limitations. First, it was a retrospective study; thus, we had missing data for some patients. It also resulted in a small patient cohort. Second, we conducted this study in multicenter. This resulted in using different laboratory devices for peripheral complete blood counting. Furthermore, surgical techniques and adjunctive treatment options might show differences between the centers. Third, we did not know the causes of death for all patients, and cancer-specific survival may differ from overall survival. All these shortcomings may have affected the outcomes.

In conclusion, SII might be an independent prognostic factor for late recurrence in patients with operable GC. If validated in well-designed prospective studies, SII could help predict long-term oncologic outcomes and help in making better treatment decisions in these patients.

**Declarations**

**Conflict of Interest** The authors declare no competing interests.

**References**

1. Xu J, Shen L, Shui Y, et al. Patterns of recurrence after curative D2 resection for gastric cancer: Implications for postoperative radiotherapy. Cancer Med. 2020;9:4724–35.
2. Wu CW, Lo SS, Shen KH, et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg. 2003;27:153–8.
3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70.
4. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32:1267–84.
5. Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51:27–41.
6. Rosales C. Neutrophil: a cell with many roles in inflammation or several cell types? Front Physiol. 2018;9:113.
7. Thomas MR, Storey RF. The role of platelets in inflammation. Thromb Haemost. 2015;114:449–58.
8. Vicente Conesa MA, Garcia-Martinez E, Gonzalez Billalabeitia E, et al. Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy. Breast. 2012;21:468–74.
9. Liu J, Li S, Zhang S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal. 2019;33:e22964.
10. Gao Y, Guo W, Cai S, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma. J Cancer. 2019;10:3188–96.
11. Unger JM, Hershman DL, Fleury ME, Vaidya R. Association of patient comorbid conditions with cancer clinical trial participation. JAMA Oncol. 2019;5:326–33.
12. Kang WM, Meng QB, Yu JC, Ma ZQ, Li ZT. Factors associated with early recurrence after curative surgery for gastric cancer. World J Gastroenterol. 2015;21:5934–40.
13. Park JM, Ryu WS, Kim JH, et al. Prognostic factors for advanced gastric cancer: stage-stratified analysis of patients who underwent curative resection. Cancer Res Treat. 2006;38:13–8.
14. Habu H, Takeshita K, Sunagawa M, Endo M. Prognostic factors of early gastric cancer—results of long-term follow-up and analysis of recurrent cases. Jpn J Surg. 1987;17:248–55.
15. Wang Q, Zhu D. The prognostic value of systemic immune-inflammation index (SII) in patients after radical operation for carcinoma of stomach in gastric cancer. J Gastrointest Oncol. 2019;10:965–78.
16. Chen L, Yan Y, Zhu L, et al. Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy. Cancer Manag Res. 2017;9:849–67.
17. Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer. 1998;1:125–33.
18. Chang SC, Liu KH, Hung CY, et al. Adjuvant chemotherapy improves survival in stage III gastric cancer after D2 surgery. J Cancer. 2018;9:81–91.
19. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.
20. Wu L, Saxena S, Awaji M, Singh RK. Tumor-associated neutrophils in cancer: going pro. Cancers (Basel). 2019;11.
21. Pilatova K, Zdrazilova-Dubska L, Klement GL. The role of platelets in tumour growth. Klin Onkol. 2012;25 Suppl 2:2S50–57.
22. Huong PT, Nguyen LT, Nguyen XB, Lee SK, Bach DH. The role of platelets in the tumor-microenvironment and the drug resistance of cancer cells. Cancers (Basel). 2019;11.
23. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15:425–30.
24. Hirahara N, Tajima Y, Matsubara T, et al. Systemic immune-inflammation index predicts overall survival in patients with gastric cancer: a propensity score-matched analysis. J Gastrointest Surg. 2020.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.